Medication-info.com Search Menu

Verzenio (Abemaciclib): Uses, Side Effects and Dosage

Status:
Prescription (Rx) Facts
Strength:
50 mg, 100 mg, 150 mg, 200 mg
Drug class:
Active ingredient:

Patient information: uses, side effects, how to take - Verzenio

What is the most important information I should know about VERZENIO?

VERZENIO may cause serious side effects including:

  • Diarrhea. Diarrhea is common with VERZENIO treatment and may sometimes be severe. Diarrhea may lead to loss of large amounts of fluid and salt causing you to develop dehydration. The most common time to develop diarrhea is during the first month of VERZENIO treatment.

    • If you develop any loose stools, start taking an antidiarrheal medicine (such as loperamide), drink more fluids, and tell your healthcare provider right away.
  • Low white blood cell counts (neutropenia). Low white blood cell counts are common during treatment with VERZENIO and may cause serious infections that can lead to death. Your healthcare provider should check your white blood cell counts before and during treatment. Tell your healthcare provider right away if you develop signs or symptoms of an infection, such as fever and chills.
  • Lung problems. VERZENIO may cause severe or life-threatening inflammation of the lungs during treatment that can lead to death. Tell your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

    • trouble breathing or shortness of breath
    • cough with or without mucus
    • chest pain
  • Liver problems. VERZENIO can cause serious liver problems. Your healthcare provider should do blood tests to check your liver before and during treatment with VERZENIO. Tell your healthcare provider right away if you develop signs and symptoms of liver problems, such as:

    • feeling very tired
    • pain on the upper right side of your stomach area (abdomen)
    • loss of appetite
    • bleeding or bruising more easily than normal
  • Blood clots in your veins, or in the arteries of your lungs. VERZENIO may cause serious blood clots that have led to death. Tell your healthcare provider right away if you develop signs or symptoms of a blood clot, such as:

    • pain or swelling in your arms or legs
    • shortness of breath
    • chest pain
    • rapid breathing
    • rapid heart rate

If you develop serious side effects during treatment with VERZENIO, your healthcare provider may reduce your dose, temporarily stop, or completely stop treatment with VERZENIO.

See “What are the possible side effects of VERZENIO?” for more information about side effects.

What is VERZENIO?

VERZENIO is a prescription medicine used in adults:

  • in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer with a high risk of coming back as determined by your healthcare provider.
  • in combination with an aromatase inhibitor as the first endocrine-based therapy to treat HR-positive, HER2-negative breast cancer that is advanced or that has spread to other parts of the body (metastatic).
  • in combination with fulvestrant to treat HR-positive, HER2-negative breast cancer that is advanced or spread to other parts of the body (metastatic) and whose disease has progressed after endocrine therapy.
  • in combination with imlunestrant to treat estrogen receptor ER-positive, HER2-negative, estrogen receptor-1 (ESR1)-mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), and whose disease has progressed after at least 1 line of endocrine therapy. Your healthcare provider will perform a test to make sure VERZENIO in combination with imlunestrant is right for you.
  • alone to treat HR-positive, HER2-negative breast cancer that is advanced or that has spread to other parts of the body (metastatic) and whose disease has progressed after endocrine therapy and prior chemotherapy for metastatic disease.

When VERZENIO is used in combination with fulvestrant, tamoxifen, imlunestrant, or an aromatase inhibitor, also read the Patient Information or Medication Guide for the prescribed product if available. Ask your healthcare provider if you are not sure.

It is not known if VERZENIO is safe and effective in children.

Before taking VERZENIO, tell your healthcare provider about all of your medical conditions, including if you:

  • have fever, chills, or any other signs of an infection.
  • have a history of blood clots in your veins.
  • have lung or breathing problems.
  • have liver or kidney problems.
  • are pregnant or plan to become pregnant. VERZENIO can harm your unborn baby.

    Females who are able to become pregnant:

    • Your healthcare provider will do a pregnancy test before you start treatment with VERZENIO.
    • Use effective birth control (contraception) during treatment with VERZENIO and for 3 weeks after the last dose of VERZENIO.
    • If you are taking VERZENIO in combination with another medicine, your healthcare provider will tell you how long you should use birth control (contraception).
    • Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with VERZENIO.
  • are breastfeeding or plan to breastfeed. It is not known if VERZENIO passes into your breast milk. Do not breastfeed during treatment with VERZENIO and for at least 3 weeks after the last dose of VERZENIO.

    • If you are taking VERZENIO in combination with another medicine, your healthcare provider will tell you how long you should not breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VERZENIO may affect the way other medicines work, and other medicines may affect how VERZENIO works, causing serious side effects.

Especially tell your healthcare provider if you take a medicine that contains ketoconazole.

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How should I take VERZENIO?

  • Take VERZENIO exactly as your healthcare provider tells you.
  • Your healthcare provider may change your dose if needed. Do not stop taking VERZENIO or change the dose without talking to your healthcare provider.
  • Take VERZENIO with or without food.

  • Swallow VERZENIO tablets whole. Do not chew, crush, or split the tablets before swallowing. Do not take VERZENIO tablets if they are broken, cracked, or damaged.
  • Take your doses of VERZENIO at about the same time every day.
  • If you miss a dose of VERZENIO, skip the missed dose and take your next dose, take your next dose at your regularly scheduled time.
  • If you vomit after taking a dose of VERZENIO, do not take another dose, take your next dose at your regularly scheduled time.

What should I avoid during treatment with VERZENIO?

  • Avoid taking ketoconazole during treatment with VERZENIO. Tell your healthcare provider if you take a medicine that contains ketoconazole.
  • Avoid grapefruit and products that contain grapefruit during treatment with VERZENIO. Grapefruit may increase the amount of VERZENIO in your blood.

What are the possible side effects of VERZENIO?

VERZENIO may cause serious side effects, including:

  • See “What is the most important information I should know about VERZENIO?”

The most common side effects of VERZENIO include:

  • diarrhea
  • infections
  • low white blood cell counts (neutropenia and leukopenia)
  • tiredness (fatigue)
  • stomach area (abdominal) pain
  • nausea
  • low red blood cell counts (anemia)
  • vomiting

VERZENIO may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of VERZENIO.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store VERZENIO?

  • Store VERZENIO at room temperature between 68°F to 77°F (20°C to 25°C).

Keep VERZENIO and all medicines out of the reach of children.

General information about the safe and effective use of VERZENIO.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VERZENIO for a condition for which it was not prescribed. Do not give VERZENIO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for more information about VERZENIO that is written for health professionals.

What are the ingredients in VERZENIO?

Active ingredient: abemaciclib

Inactive ingredients: microcrystalline cellulose 102, microcrystalline cellulose 101, lactose monohydrate, croscarmellose sodium, sodium stearyl fumarate, silicon dioxide.

Color mixture ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow, iron oxide red.

Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA

Copyright © 2017, 2026, Eli Lilly and Company. All rights reserved.

VER-0006-PPI-20260918

For more information, go to www.verzenio.com or call 1-800-545-5979.

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: NDA 208716 · View the label on DailyMed

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Verzenio

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Drug class Kinase Inhibitor
Active ingredient Abemaciclib
Dosage form Tablet
Route Oral
Marketing status not in the current FDA NDC Directory
Company (applicant) ELI LILLY AND CO
FDA approval NDA 208716New Drug Application (NDA) Approved September 28, 2017
Reference listed drug This is the reference listed drug (RLD) that generics are compared with.
Manufacturers 1 labelers list this drug on DailyMed
Packages (NDC)
Package
50 mg – 14 in 1 blister pack / 1 in 1 carton NDC 0002-4483-54
50 mg – 14 in 1 blister pack / 2 in 1 carton NDC 0002-4483-62
100 mg – 14 in 1 blister pack / 1 in 1 carton NDC 0002-4815-54
100 mg – 14 in 1 blister pack / 2 in 1 carton NDC 0002-4815-62
150 mg – 14 in 1 blister pack / 1 in 1 carton NDC 0002-5337-54
150 mg – 14 in 1 blister pack / 4 in 1 carton / 1 in 1 carton NDC 0002-5337-63
150 mg – 14 in 1 blister pack / 2 in 1 carton NDC 0002-5337-62
200 mg – 14 in 1 blister pack / 1 in 1 carton NDC 0002-6216-54

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.